Fully human bispecific IgG4 monoclonal antibody intended to engage immune effectors to kill malignant B cells (specific targets not stated).
Fully human bispecific IgG4 antibody that binds CD3 on T cells and CD19 on B cells, physically redirecting cytotoxic T lymphocytes to CD19+ malignant B cells to induce perforin/granzyme-mediated killing. The fixed-light-chain arm weakly activates CD3, while the heavy-chain-only arm binds CD19 with high affinity, enabling MHC-independent T-cell engagement and tumor cell lysis.
YES
DIRECT
Bispecific antibody bridges CD3 on T cells to CD19 on target cells, redirecting CTLs to form an immune synapse and kill CD19+ cells via perforin/granzyme-mediated cytolysis.
Fully human bispecific IgG4 monoclonal antibody intended to engage immune effectors to kill malignant B cells (specific targets not stated).
Fully human bispecific IgG4 antibody that binds CD3 on T cells and CD19 on B cells, physically redirecting cytotoxic T lymphocytes to CD19+ malignant B cells to induce perforin/granzyme-mediated killing. The fixed-light-chain arm weakly activates CD3, while the heavy-chain-only arm binds CD19 with high affinity, enabling MHC-independent T-cell engagement and tumor cell lysis.
NO
INDIRECT
The bispecific antibody binds CD3 on T cells to engage and activate them, redirecting perforin/granzyme-mediated cytotoxicity against CD19+ B cells; CD3+ cells are not targeted for lysis.
Chimeric anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via ADCC, complement activation (CDC), and apoptosis.
Chimeric anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and engages immune effectors via its Fc to mediate ADCC; it also activates complement for CDC and can induce apoptosis upon CD20 crosslinking, leading to killing of CD20+ cells.
Anti-HER2 humanized monoclonal antibody that binds ERBB2 (HER2) to inhibit signaling and mediate antibody-dependent cellular cytotoxicity.
Humanized anti-HER2 monoclonal antibody that binds ERBB2 (HER2) on tumor cells, blocks HER2 signaling and growth, and mediates antibody-dependent cell-mediated cytotoxicity via Fc receptor–bearing immune cells.
YES
DIRECT
Trastuzumab binds HER2 on target cells and engages Fcγ receptor–bearing immune cells (e.g., NK cells, macrophages) to mediate antibody-dependent cellular cytotoxicity; may also activate complement and induce apoptosis.
Cetuximab-like anti-EGFR monoclonal antibody that binds EGFR to inhibit ligand-driven signaling and mediates Fc-dependent cytotoxicity (ADCC, ADCP).
Unconjugated monoclonal antibody that binds EGFR, blocks ligand-driven receptor activation and downstream signaling (e.g., RAS/MAPK, PI3K/AKT), and engages Fc receptors to elicit immune effector functions including ADCC and ADCP against EGFR-expressing tumor cells.
YES
DIRECT
Antibody binding to EGFR opsonizes target cells and engages Fcγ receptors on effector cells, leading to ADCC by NK cells and ADCP by macrophages, killing EGFR+ cells.